S 
Scientific and Medical Equipment House Company CJSC 4014.SR · SAR
Health Care · Tadawul · 🇸🇦 Saudi Arabia
26.74
—
Close of 9 Nov 2026, in SAR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in SAR, from our data supplier.
Revenue
SAR 876.7m
FY2017FY2025
Net income
SAR 28.4m
FY2017FY2025
Free cash flow
−SAR 12.8m
FY2017FY2025
Shareholders' equity
SAR 508.7m
FY2017FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | SAR 876.7m | SAR 877.2m | SAR 799.3m | SAR 713.8m | SAR 699.5m | SAR 652.4m | SAR 597.0m | SAR 583.9m | SAR 555.9m |
| Operating income | SAR 40.2m | SAR 39.3m | SAR 68.7m | SAR 50.7m | SAR 98.8m | SAR 96.3m | SAR 91.9m | SAR 85.0m | SAR 71.6m |
| Net income | SAR 28.4m | SAR 24.6m | SAR 40.1m | SAR 17.6m | SAR 77.5m | SAR 74.8m | SAR 49.5m | SAR 68.1m | SAR 49.4m |
| Diluted earnings per share | 0.30 | 0.82 | 1.34 | 0.59 | 3.88 | 2.50 | 2.47 | 3.40 | 2.47 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | SAR 933.4m | SAR 951.8m | SAR 1.10bn | SAR 931.0m | SAR 1.02bn | SAR 889.4m | SAR 861.8m | SAR 845.3m | SAR 657.3m |
| Cash and short-term investments | SAR 20.5m | SAR 88.1m | SAR 16.9m | SAR 54.6m | SAR 45.3m | SAR 474.8m | SAR 540.2m | SAR 570.4m | SAR 62.8m |
| Total liabilities | SAR 432.6m | SAR 446.8m | SAR 597.3m | SAR 462.4m | SAR 544.1m | SAR 889.4m | SAR 861.8m | SAR 845.3m | SAR 657.3m |
| Debt | SAR 184.0m | SAR 208.2m | SAR 362.8m | SAR 206.6m | SAR 266.2m | SAR 191.5m | SAR 236.4m | SAR 287.8m | SAR 171.7m |
| Shareholders' equity | SAR 508.7m | SAR 510.6m | SAR 510.8m | SAR 470.4m | SAR 473.5m | SAR 428.0m | SAR 355.9m | SAR 300.7m | SAR 254.1m |
| Shares outstanding | 96m | 30m | 30m | 30m | 20m | 30m | 20m | 20m | 20m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −SAR 5.7m | SAR 285.8m | −SAR 140.6m | SAR 124.0m | −SAR 84.7m | SAR 117.3m | SAR 162.8m | −SAR 108.6m | SAR 77.9m |
| Capital spending | −SAR 7.1m | −SAR 4.4m | −SAR 14.9m | −SAR 17.8m | −SAR 7.4m | −SAR 23.0m | −SAR 10.5m | −SAR 3.0m | −SAR 3.2m |
| Free cash flow | −SAR 12.8m | SAR 281.4m | −SAR 155.5m | SAR 106.2m | −SAR 92.2m | SAR 94.3m | SAR 152.3m | −SAR 111.5m | SAR 74.7m |
| Dividends paid | −SAR 30.0m | −SAR 30.0m | — | −SAR 20.0m | −SAR 30.0m | −SAR 30.0m | −SAR 20.0m | −SAR 20.0m | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | SAR 211.9m | SAR 192.1m | SAR 181.9m | SAR 200.5m | SAR 272.0m | SAR 221.7m | SAR 227.2m | SAR 218.4m |
| Operating income | SAR 16.8m | SAR 8.6m | SAR 3.5m | SAR 10.3m | SAR 19.8m | SAR 13.8m | −SAR 52.0m | SAR 17.3m |
| Net income | SAR 10.9m | SAR 8.3m | SAR 711,585 | SAR 7.7m | SAR 12.4m | SAR 7.7m | −SAR 2.7m | SAR 10.9m |
| Diluted earnings per share | 0.36 | 0.28 | 0.01 | 0.08 | 0.13 | 0.08 | -0.09 | 0.36 |
| Cash from operations | −SAR 9.0m | SAR 50.0m | −SAR 12.0m | SAR 45.0m | −SAR 84.0m | SAR 52.0m | SAR 22.0m | SAR 130.0m |
| Capital spending | — | −SAR 1.0m | −SAR 1.0m | −SAR 1.0m | −SAR 1.0m | −SAR 2.0m | −SAR 3.0m | −SAR 1.0m |
| Free cash flow | — | SAR 49.0m | −SAR 13.0m | SAR 44.0m | −SAR 85.0m | SAR 50.0m | SAR 19.0m | SAR 129.0m |
| Total assets | SAR 1.01bn | SAR 941.4m | SAR 933.4m | SAR 941.1m | SAR 983.1m | SAR 900.8m | SAR 951.8m | SAR 997.9m |
| Cash and short-term investments | — | — | SAR 20.5m | SAR 23.9m | SAR 27.3m | SAR 66.1m | SAR 88.1m | SAR 96.8m |
| Debt | SAR 10.8m | SAR 4.4m | SAR 184.0m | SAR 168.9m | SAR 185.3m | SAR 133.2m | SAR 199.1m | SAR 190.7m |
| Shareholders' equity | SAR 498.7m | SAR 517.0m | SAR 508.7m | SAR 508.3m | SAR 530.7m | SAR 518.3m | SAR 533.3m | SAR 538.1m |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 7.1% | 6.1% | — |
| Operating income | -7.4% | -16.0% | — |
| Net income | 17.4% | -17.6% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Price to earnings | 107.2 | 61.6 | 35.8 | 69.6 |
| Price to sales | 3.5 | 1.7 | 1.8 | 1.7 |
Dividends and splits
Per share, in the currency the company pays
Paid for 2 years. Last went ex-dividend on 10 Sept 2025.
| FY2025 | FY2024 | FY2022 | |
|---|---|---|---|
| Paid in the year | 1.00 | 1.00 | 0.667 |
- 3-for-2 split · 4 Sept 2023
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.